Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
243 hedge funds and large institutions have $4.39B invested in Mirati Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 97 increasing their positions, 71 reducing their positions, and 26 closing their positions.
58% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 26
37% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 71
15% more funds holding in top 10
Funds holding in top 10: 13 → 15 (+2)
11% more capital invested
Capital invested by funds: $3.95B → $4.39B (+$437M)
6% more funds holding
Funds holding: 230 → 243 (+13)
20% less call options, than puts
Call options by funds: $70.3M | Put options by funds: $87.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$105M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$99.9M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$75.1M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$53.3M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$41.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$165M |
| 2 |
SCM
Suvretta Capital Management
New York
|
-$63.9M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$48.7M |
| 4 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
-$38.5M |
| 5 |
Bank of New York Mellon
New York
|
-$34.6M |
MRTX Hedge Fund Activity: Q3 2022 in Review
243 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q3 2022, worth a combined $4.39B — up 11% from $3.95B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new MRTX positions and 26 closed out — a net gain of 15 holders — while 97 added to existing stakes and 71 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $105M. The largest seller was Goldman Sachs, cutting an estimated $165M.
- 243 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q3 2022, up from 230 in Q2 2022.
- Funds reported $4.39B of Mirati Therapeutics, Inc. Common Stock stock for Q3 2022, up 11% quarter-over-quarter.
- 41 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q3 2022 and 26 closed out, a net change of +15 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q3 2022 was Adage Capital Partners, an estimated $105M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q3 2022 was Goldman Sachs, an estimated $165M sold.
Based on aggregated 13F filings for Q3 2022.